A Pathway-Driven Computational Drug Discovery Framework Integrating Machine Learning and Virtual Screening for Identification of Anti-Rheumatoid Arthritis Natural Small Molecules.
Source check: Source checked. Not independent scientific confirmation.
Finding: A pathway-guided ML workflow selects natural-molecule candidates for rheumatoid arthritis and tests prioritized compounds in an in-vitro inflammatory model after docking and molecular-dynamics analyses; the evidence supports those assay results, not therapeutic efficacy.
Technology: Pathway-guided machine learning ranks rheumatoid-arthritis target candidates and natural molecules; docking and molecular-dynamics analyses prioritize compounds for cellular testing.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Pathway-guided machine learning ranks rheumatoid-arthritis target candidates and natural molecules; docking and molecular-dynamics analyses prioritize compounds for cellular testing.
- Test and result
- Machine-learning ranking and virtual screening selected compounds; the paper reports reduced IL6/MMP3 in TNFα-stimulated MH7A cells after SM1 treatment. These in-vitro findings do not establish therapeutic efficacy.
- Limitation / still unknown
- Primary Methods/Results establish the cohort or experiment, comparison and stated validation limits.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://mdpi-res.com/d_attachment/pharmaceuticals/pharmaceuticals-19-01651/article_deploy/pharmaceuticals-19-01651.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.